We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-21.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.63B
AUM Growth
-$1.11B
(-30%)
Cap. Flow
-$123M
Cap. Flow
% of AUM
-4.66%
Top 10 Holdings %
Top 10 Hldgs %
51.48%
Holding
146
New
29
Increased
20
Reduced
29
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Solid Biosciences
SLDB
|
+$123M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$77.8M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$47.7M |
| 4 |
Allogene Therapeutics
ALLO
|
+$41M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$39M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$72M |
| 2 |
CORI
Corium International, Inc.
CORI
|
+$60.5M |
| 3 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$43.4M |
| 4 |
Intuitive Surgical
ISRG
|
+$41.6M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$37.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.94% |
| 2 | Miscellaneous | 1.24% |
| 3 | Consumer Staples | 0.68% |
| 4 | Financials | 0.08% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EIDX
51
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $9.45M | 0.36% |
686,922
| – | – |
|
52
Akebia Therapeutics
AKBA
$250M
| $9.18M | 0.35% |
1,703,440
-746,081
| -30% | -$5.84M |
|
|
ORTX
53
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $8.21M | 0.31% |
+52,180
| New | +$7.78M |
|
54
Collegium Pharmaceutical
COLL
$711M
| $7.37M | 0.28% |
+445,000
| New | +$7.61M |
|
55
Zymeworks
ZYME
$1.86B
| $7.2M | 0.27% |
573,890
-550,000
| -49% | -$7.22M |
|
|
MTEM
56
DELISTED
Molecular Templates, Inc.
MTEM
| $7.11M | 0.27% |
131,609
| – | – |
|
57
Xencor
XNCR
$1.77B
| $6.83M | 0.26% |
196,810
-631,285
| -76% | -$23.2M |
|
|
SYBX
58
DELISTED
Synlogic
SYBX
| $6.05M | 0.23% |
57,857
-5,000
| -8% | -$658K |
|
59
uniQure
QURE
$2.99B
| $5.95M | 0.23% |
220,707
-752,124
| -77% | -$20.9M |
|
60
TherapeuticsMD
TXMD
$25M
| $5.71M | 0.22% |
30,000
| – | – |
|
|
DBVT
61
DBV Technologies
DBVT
$739M
| $5.31M | 0.2% |
82,696
-218,304
| -73% | -$35.1M |
|
|
MRTX
62
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $5.25M | 0.2% |
+125,875
| New | +$5.02M |
|
|
UROV
63
DELISTED
Urovant Sciences Ltd.
UROV
| $3.92M | 0.15% |
625,359
+162,700
| +35% | +$1.48M |
|
64
Arrowhead Research
ARWR
$9.98B
| $3.58M | 0.14% |
300,000
-65,445
| -18% | -$895K |
|
65
Rocket Pharmaceuticals
RCKT
$374M
| $3.5M | 0.13% |
+240,173
| New | +$3.99M |
|
|
SRRA
66
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.41M | 0.13% |
66,655
-13,345
| -17% | -$852K |
|
|
TBIO
67
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $3.17M | 0.12% |
435,000
-65,000
| -13% | -$476K |
|
68
Teladoc Health
TDOC
$1.2B
| $2.97M | 0.11% |
+60,000
| New | +$3.67M |
|
69
Wave Life Sciences
WVE
$879M
| $2.5M | 0.1% |
59,498
-174,521
| -75% | -$7.76M |
|
70
eHealth
EHTH
$28.5M
| $2.11M | 0.08% |
55,021
-171,199
| -76% | -$5.76M |
|
71
Penumbra
PEN
$12.5B
| $2.04M | 0.08% |
+16,338
| New | +$2.19M |
|
72
Veru
VERU
$39.9M
| $1.85M | 0.07% |
142,500
| – | – |
|
|
GRCE
73
Grace Therapeutics
GRCE
$46.9M
| $1.48M | 0.06% |
+37,081
| New | +$1.62M |
|
|
EIGR
74
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.42M | 0.05% |
4,663
-593
| -11% | -$192K |
|
|
OMED
75
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $1.28M | 0.05% |
1,719,111
-901,786
| -34% | -$1.36M |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q4 2018 Portfolio in Review
As of Q4 2018, Perceptive Advisors held 146 positions worth $2.63B, down 30% from $3.74B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Perceptive Advisors withdrew a net $123M in Q4 2018, closing 45 positions and reducing 29 holdings. Its most notable exit was Corium International, Inc., an estimated $60.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Miscellaneous and Consumer Staples.
Against the trend, Perceptive Advisors opened a new position in Solid Biosciences worth $105M.
- Perceptive Advisors's largest Q4 2018 buy was Solid Biosciences: 261,815 shares worth $105M.
- Perceptive Advisors added most to Amarin Corp in Q4 2018, an estimated $77.8M increase.
- Perceptive Advisors's biggest Q4 2018 reduction was Alnylam Pharmaceuticals, cutting an estimated $72M.
- Perceptive Advisors fully exited Corium International, Inc. in Q4 2018, selling an estimated $60.5M.
- Perceptive Advisors's ten largest holdings make up 51% of its $2.63B portfolio in Q4 2018.
- Perceptive Advisors opened 29 new positions and closed 45 in Q4 2018.
- Perceptive Advisors's portfolio value fell 30% quarter-over-quarter to $2.63B.
Based on Perceptive Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.